FINWIRES · TerminalLIVE
FINWIRES

Vera Therapeutics Aligns With FDA on Earlier Atacicept Analysis to Support Potential Full Approval

By

Vera Therapeutics (VERA) said Tuesday it aligned with the US Food and Drug Administration on a revised analysis plan for its phase 3 Origin trial of atacicept in adults with IgA nephropathy.

The biotechnology company said estimated glomerular filtration rate results from the trial are now expected in Q3. Pending those results, Vera plans to submit a supplemental biologics license application for full approval in Q4.

Vera said the FDA alignment was supported by phase 2b Origin trial results showing significant reductions in proteinuria, stabilization of kidney function and a placebo-comparable safety profile, while its phase 3 Origin trial met its primary endpoint and remains ongoing to evaluate eGFR changes.

Atacicept has received FDA Breakthrough Therapy Designation for IgAN, and Vera is also studying the drug in other kidney diseases, with enrollment completed in a separate dose-ranging study, the company said.

Shares of Vera Therapeutics were down more than 6% in Tuesday trading.

Price: $31.76, Change: $-2.18, Percent Change: -6.42%

Related Articles

Wire

Update: Northern Star Resources Should Launch Strategic Review, Explore Sale, Activist Investor Elliott Says; Shares Up 9%

(Updates to add stock movement in the headline and last paragraph)Northern Star Resources (ASX:NST) should conduct a strategic review that includes a potential sale, alongside a search for a new CEO, to identify opportunities for operational improvements, shareholder Elliott Investment Management said Monday.Elliott disclosed a stake of over AU$1 billion in Northern Star Resources, saying it wants to work with the company to maximize shareholder value."Northern Star's recent pattern of operational missteps, cost overruns and inconsistent strategic direction demands urgent action," Elliott said, adding that the company has underperformed its potential despite holding world-class gold assets.The activist investor also urged the company to supplement its board with "fresh perspectives" to help guide the review and subsequent steps.Elliott further alleged that Northern Star has "deeply inadequate disclosures compared to global senior peers." The company is likely to draw "significant strategic interest" if it explores a sale, Elliott said.Northern Star Resources did not immediately reply to a request for comment from.The company's shares rose around 9% in recent Tuesday trade.

ASX:NST
Wire

Xometry Plans Offering of Class A Shares

Xometry (XMTR) said Monday it has started an underwritten public offering of $225 million of its Class A shares, subject to market conditions.Underwriters will be given a 30-day option to buy up to an additional $33.75 million of shares, the company said.Net proceeds from the planned offering are for working capital and general corporate purposes, Xometry said.Xometry shares were down past 9% in after-hours activity.

$XMTR
Wire

LXP Industrial Trust Revises 2026 Adjusted FFO Guidance

LXP Industrial Trust (LXP) said late Monday it now expects 2026 adjusted funds from operations per diluted share of $3.30 to $3.40 from $3.22 to $3.37 earlier.Analysts polled by FactSet expected $3.28.In May, the company acquired a 37-acre infill industrial redevelopment site in the South Airport submarket of Phoenix for $103 million, according to a statement.The site produces annual rent of $16.1 million, with 2% annual rent hikes, the company said.

$LXP